Myeloproliferative Neoplasm
Showing NaN - NaN of 9
MDS, Myeloproliferative Tumor, Anemia Trial in Tampa (Luspatercept)
Recruiting
- Myelodysplastic Syndromes
- +2 more
-
Tampa, FloridaMoffitt Cancer Center
Feb 16, 2023
Acute Myeloid Leukemia, Down Syndrome, Myelodysplastic Syndrome Trial in Worldwide (Asparaginase, Asparaginase Erwinia
Active, not recruiting
- Acute Myeloid Leukemia
- +4 more
- Asparaginase
- +7 more
-
Birmingham, Alabama
- +190 more
Jan 30, 2023
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia Trial in Tampa (Fludarabine, Melphalan, Total
Active, not recruiting
- Acute Myeloid Leukemia
- +17 more
- Fludarabine
- +2 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center & Research Institute
Jan 10, 2023
Myeloproliferative Tumor Trial in Tampa (Fedratinib Pill)
Recruiting
- Myeloproliferative Neoplasm
- Fedratinib Pill
-
Tampa, FloridaMoffitt Cancer Center
Nov 28, 2022
Project: Every Child for Younger Patients With Cancer
Recruiting
- Carcinoma In Situ
- +10 more
- Cytology Specimen Collection Procedure
- Medical Chart Review
-
Birmingham, Alabama
- +240 more
Oct 19, 2022
Myeloproliferative Tumor, Chronic Neutrophilic Leukemia, MDS Trial in Tampa (Fedratinib Pill)
Recruiting
- Myeloproliferative Neoplasm
- +2 more
- Fedratinib Pill
-
Tampa, FloridaMoffitt Cancer Center
Jun 15, 2022
Blastic Plasmacytoid Dendritic Cell Tumor, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia Trial in Worldwide (IMGN632)
Recruiting
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- +3 more
-
Gilbert, Arizona
- +14 more
Apr 20, 2022
Myelodysplastic Syndrome, Acute Myeloid Leukemia, Myeloproliferative Tumor Trial in United States (APR-246, Azacitidine)
Completed
- Myelodysplastic Syndrome
- +3 more
-
Tampa, Florida
- +5 more
Jan 14, 2022
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Myeloproliferative Tumor, Recurrent Acute Lymphoblastic Leukemia Trial
Completed
- Allogeneic Hematopoietic Stem Cell Transplant Recipient
- +10 more
- Ipilimumab
- +2 more
-
Duarte, California
- +12 more
Jun 23, 2021